文献速递甲状腺疾病

分化型甲状腺癌的风险分层:从检测到最终随访

Risk Stratification in Differentiated Thyroid Cancer: From Detection to Final Follow-Up.
PubMed 文献 · J Clin Endocrinol Metab · 2019-01-01

本文综述了分化型甲状腺癌风险分层的演变,从基于临床病理特征的静态死亡风险估计,转变为贯穿可疑结节检测至最终随访的动态、迭代过程,用于指导初始治疗强度、复发风险及治疗反应评估。

要点

  • 风险分层应始于可疑结节检测,贯穿初始治疗至最终随访全过程。
  • 现代风险分层需预测初始治疗适宜性、疾病特异性死亡、复发风险及治疗反应。
  • 动态风险评估应指导分化型甲状腺癌管理的各个方面。

核心结论

  • 动态风险评估应指导分化型甲状腺癌管理的各个方面,从明确诊断前开始并持续至最终随访。

研究设计与样本

  • 基于作者知识与广泛临床经验,辅以已发表的综述、甲状腺癌管理指南、分期系统及PubMed检索的原始文章。

主要发现

  • 过去风险分层通常指基于初始治疗后数周内可用的小组临床病理特征对疾病特异性死亡率的静态估计。
  • 如今风险分层是动态、主动的过程,用于预测最小化初始治疗的适宜性、疾病特异性死亡、复发风险及对初始治疗的最可能反应。

临床怎么用

  • 临床应使用动态风险评估指导分化型甲状腺癌从检测到最终随访的全部管理环节。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

CONTEXT: Modern management of differentiated thyroid cancer requires individualized care plans that tailor the intensity of therapy and follow-up to the estimated risks of recurrence and disease-specific mortality. DESIGN: This summary is based on the authors' knowledge and extensive clinical experience, supplemented by review of published review articles, thyroid cancer management guidelines, published staging systems, and original articles identified through a PubMed search, which included terms such as risk stratification, staging, clinical outcomes, and differentiated thyroid cancer. MAIN OUTCOME MEASURES: In the past, risk stratification in differentiated thyroid cancer usually referred to a static estimate of disease-specific mortality that was based on a small set of clinicopathological features available within a few weeks of completing initial therapy (thyroidectomy, with or without radioactive iodine). Today, risk stratification is a dynamic, active process used to predict the appropriateness for minimalistic initial therapy, disease-specific mortality, risk of recurrence, and the most likely response to initial therapy. Rather than being a static prediction available only after initial therapy, modern risk stratification is a dynamic, iterative process that begins as soon as a suspicious nodule is detected and continues through final follow-up. CONCLUSIONS: Dynamic risk assessment should be used to guide all aspects of thyroid cancer management, beginning before a definitive diagnosis is made and continuing through the final follow-up visit.

来源:J Clin Endocrinol Metab,查看原文。版权归原作者所有。

引用

  1. Tuttle RM, Alzahrani AS. Risk Stratification in Differentiated Thyroid Cancer: From Detection to Final Follow-Up. J Clin Endocrinol Metab. 2019. PMID: 30874735. doi:10.1210/jc.2019-00177

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。